登革病毒嵌合蛋白的设计与制备及其用于开发四价疫苗的潜力
研究从南美登革病毒分离株序列出发,通过生物信息学比对和线性B表位预测,设计并制备了11种嵌合肽,用登革病毒1–4型感染者血清进行ELISA检测;其中EnvEpII蛋白联合铝佐剂免疫BALB/c和C57BL/6小鼠后,诱导了T CD4+、CD8+细胞增多、IgG1和IgG2抗体高产生以及IL-2和IL-17升高。
要点
- 基于四个登革病毒血清型高度同源区和非保守抗原区设计了11种嵌合肽。
- EnvEpII蛋白联合铝佐剂免疫两种小鼠均诱导了细胞和体液免疫应答。
- 作者认为生物信息学表位筛选可用于重组蛋白疫苗候选开发。
核心结论
- EnvEpII蛋白联合铝佐剂在小鼠中诱导了有效的细胞应答和强烈的体液应答,作者认为其类似于针对登革病毒感染的有效特异性应答。
- 作者指出,尽管需要进一步实验,结果提示通过生物信息学工具筛选表位可有效创建重组蛋白,作为传染病疫苗开发的候选。
研究设计与样本
- 从NCBI/Virus Variation/登革病毒数据库下载南美登革病毒分离株序列,进行血清型内比对生成四个共识序列。
- 用BLAST检索四条同源登革病毒序列并进行血清型间比对,同时进行线性B表位预测分析。
- 利用登革病毒C、prM、E和NS1蛋白中高度同源区、非保守抗原区及最具抗原性表位构建11种嵌合肽。
- 嵌合蛋白基因经商业合成,蛋白表达后经亲和层析纯化,用登革病毒1、2、3或4型感染者血清进行ELISA检测。
- 作为概念验证,选择嵌合EnvEpII蛋白免疫BALB/c和C57BL/6小鼠。
主要发现
- EnvEpII蛋白联合铝佐剂在BALB/c和C57BL/6两种小鼠中均诱导T CD4+和CD8+细胞数量增加。
- EnvEpII蛋白联合铝佐剂在两种小鼠中均诱导IgG1和IgG2抗体高产生。
- EnvEpII蛋白联合铝佐剂在两种小鼠中均诱导IL-2和IL-17细胞因子水平升高。
- 作者指出EnvEpII蛋白联合铝佐剂通过刺激IL-2、IL-4、IL-17产生诱导有效细胞应答,并诱导强烈体液应答。
局限性
- 作者指出需要进一步实验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dengue virus (DENV) is a Flavivirus estimated to cause 390 million infections/year. Currently, there is no anti-viral specific treatment for dengue, and efficient DENV vector control is still unfeasible. Here, we designed and produced chimeric proteins containing potential immunogenic epitopes from the four DENV serotypes in an attempt to further compose safer, balanced tetravalent dengue vaccines. For this, South American DENV isolate sequences were downloaded from the NCBI/Virus Variation/Dengue virus databases and intraserotype-aligned to generate four consensuses. Four homologous DENV sequences were retrieved using BLAST and then interserotype-aligned. In parallel, sequences were subjected to linear B epitope prediction analysis. Regions of the envelope and NS1 proteins that are highly homologous among the four DENV serotypes, non-conserved antigenic regions and the most antigenic epitopes found in the C, prM, E and NS1 DENV proteins were used to construct 11 chimeric peptides. Genes encoding the chimeric proteins were commercially synthesized, and proteins were expressed, purified by affinity chromatography and further subjected to ELISA assays using sera from individuals infected with DENVs 1, 2, 3 or 4. As a proof-of-concept, the chimeric EnvEpII protein was selected to immunize BALB/c and C57BL/6 mice strains. The immunization with EnvEpII protein associated with aluminum induced an increased number of T CD4+ and CD8+ cells, high production of IgG1 and IgG2 antibodies, and increased levels of IL-2 and IL-17 cytokines, in both mouse strains. Because the EnvEpII protein associated with aluminum induced an efficient cellular response by stimulating the production of IL-2, IL-4, IL-17 and induced a robust humoral response in mice, we conclude that it resembles an efficient specific response against DENV infection. Although further experiments are required, our results indicate that epitope selection by bioinformatic tools is efficient to create recombinant proteins that can be used as candidates for the development of vaccines against infectious diseases.
引用
- Batista ICA, Quinan BR, Rocha Alves ÉA, et al. Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines. Vaccine. 2020. PMID: 31982262. doi:10.1016/j.vaccine.2020.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。